Found 177 matches for
The University's latest Recognition of Distinction Exercise has awarded the Nuffield Department of Medicine three new Professors; Elisabeth Ashley - Professor of Tropical Medicine. Stuart Blacksell - Professor of Tropical Microbiology and John B Davis - Professor of Pharmaceutical Discovery.
16 June 2021
The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has found that a monoclonal antibody combination developed by US company Regeneron reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response.
11 June 2021
The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.
28 May 2021
The University of Oxford has today announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. The Pandemic Sciences Centre will harness the strong global research collaborations that the University of Oxford has developed over more than forty years. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats.
21 May 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has been named David Sackett Trial of the Year by the Society for Clinical Trials (SCT). The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.
17 May 2021
The partnership will enable global genomic sequencing and examination through a specialist platform developed on Oracle Cloud Infrastructure to help mitigate the impact of potentially dangerous COVID-19 variants.
12 May 2021
The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship five of which are from the Nuffield Department of Medicine. All were selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.
10 May 2021
Professor Adrian Hill, Director of the Jenner Institute becomes a Fellow for his leading role in the design and development of new vaccines for globally important infectious diseases over the course of over 25 years. He has demonstrated that non-replicating vectored vaccines, particularly simian adenoviruses used in heterologous prime-boost immunisation regimes, can protect safely through cellular as well as humoral immunity – supporting new vaccination approaches for malaria and Ebola.
National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines
23 April 2021
Data from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population. This major community surveillance survey, one of the NIHR’s COVID-19 urgent public health studies, is a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC).
CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake
14 April 2021
You are cordially invited to join the CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake. As a commemoration of the 512 Wenchuan Earthquake in 2008, experts will share with you an update on the latest Health-EDRM Education and Research in China. This is a webinar of the CCOUC 10th Anniversary International Webinar Series on Health Emergency and Disaster Risk Management.
6 April 2021
The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.
24 March 2021
Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival. From having no known effective drugs when the pandemic first erupted, patients are now offered treatments that have been robustly proven to reduce death and improve other outcomes, such as the length of hospital stay and the need for mechanical ventilation.
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
10 March 2021
Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford’s Big Data Institute. Professor Lindgren will take up post on 1 April 2021. She succeeds Professor Gil McVean who was the founding director of the BDI, and Interim Director, Professor Martin Landray.
5 March 2021
NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts’ (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.
18 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said ‘The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies".
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease
15 February 2021
Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).
12 February 2021
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19.
10 February 2021
Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.
29 January 2021
The CRUK Oxford Centre is pleased to announce the appointment of Professor Tim Elliot as its new co-Director. Tim has recently joined the Nuffield Department of Medicine and Oriel College as the Kidani Professor of Immuno-Oncology. He re-joins the Oxford community from Southampton University, having previously completed his undergraduate degree in Biochemistry at Balliol and subsequently holding a Professorial post at the Weatherall Institute for Molecular Medicine.
Lateral flow devices detect most infectious COVID-19 cases and could allow a safer relaxation of the current lockdown
22 January 2021
Researchers from NDM's Big Data Institute working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious